4//SEC Filing
Elsbernd Brian 4
Accession 0001161697-25-000085
CIK 0001369568other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 5:00 PM ET
Size
14.4 KB
Accession
0001161697-25-000085
Insider Transaction Report
Form 4
Elsbernd Brian
Chief Compliance/Legal Officer
Transactions
- Sale
Common Stock, par value $0.001 per share
2025-03-03$23.23/sh−9,720$225,796→ 188,564 total - Exercise/Conversion
Common Stock, par value $0.001 per share
2025-03-03$2.24/sh+53,255$119,291→ 241,819 total - Exercise/Conversion
Common Stock, par value $0.001 per share
2025-03-03$2.24/sh+9,270$20,765→ 197,834 total - Sale
Common Stock, par value $0.001 per share
2025-03-03$22.93/sh−53,255$1,221,137→ 188,564 total - Exercise/Conversion
Options to Purchase Common Stock
2025-03-03−53,255→ 1,009,084 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (53,255 underlying) - Exercise/Conversion
Options to Purchase Common Stock
2025-03-03−9,270→ 1,062,339 totalExercise: $2.24Exp: 2025-12-19→ Common Stock (9,270 underlying)
Footnotes (4)
- [F1]Shares were sold for personal reasons and not as a result of a disagreement with the Company.
- [F2]Represents a weighted average price for the shares sold. Shares were sold in a range from $23.21 to $23.24 per share.
- [F3]Represents a weighted average price for the shares sold. Shares were sold in a range from $22.75 to $23.13 per share.
- [F4]Options vested in three annual tranches beginning on December 19, 2019.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001763511
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 5:00 PM ET
- Size
- 14.4 KB